JAMA Oncology

Oncology & Cancer

Taxane + platinum feasible for adjuvant tx in endometrial cancer

(HealthDay)—Taxane plus platinum regimens may be a reasonable alternative to doxorubicin plus cisplatin as postoperative adjuvant chemotherapy for endometrial cancer that carries a high risk for progression, according to ...

Oncology & Cancer

Prophylactic cranial irradiation: Improvements for advanced NSCLC

Prophylactic cranial irradiation (PCI), a technique used to prevent the clinical development of brain metastases, is established as a standard approach for many patients with small cell lung cancer (SCLC) after initial therapy. ...

Oncology & Cancer

Long-term cardiomyopathy risk varies by chemo agent

(HealthDay)—Long-term cardiomyopathy risk varies by chemotherapy agent for childhood cancer survivors, with a decreased risk for daunorubicin versus doxorubicin, according to a study recently published in JAMA Oncology.

Oncology & Cancer

Lifestyle changes can lower your breast cancer risk

(HealthDay)—While genetics, such as carrying BRCA gene mutations, play a role in who is more likely to get breast cancer, everyday lifestyle factors are involved, too.

Oncology & Cancer

Neuroendocrine tumors: Choosing the best treatment

An increasing number of new anti-cancer drugs are approved each year. During the authorization process, such new drugs usually undergo comparisons to other single drugs, but only rarely to multiple established drugs. This ...

Oncology & Cancer

Study finds HIV+ cancer patients benefit from immunotherapy

The immunotherapy that has revolutionized treatment of many cancers appears to offer similar benefit to cancer patients living with HIV, say researchers at Georgetown Lombardi Comprehensive Cancer Center.

page 30 from 40